InvestSMART

ReNerve Limited (ASX:RNV)

ALERT: Price-sensitive ASX Announcement for RNV
Current share price for RNV : $0.080 0.003 (3.90%)+
Announcement
Release
29 Jul 2026 9:24AM
Price at Release
$0.077
Full Release
download
Summary
ReNerve Limited has reported a strong Q4 FY26, with record quarterly sales of A$211,000 and an 88% increase in annual sales compared to FY25. The company secured a $5 million funding facility with Riverfort to enhance its cash position, leveraging future R&D tax rebates. The quarter was marked by successful market expansion initiatives in the Asia-Pacific region, including new distribution partnerships in Malaysia and Hong Kong, and securing marketing approval in Indonesia. ReNerve also advanced its NervAlign® Nerve Guide Matrix program to Stage 3, aimed at FDA submission, and demonstrated significant progress in its commercial and operational strategies.
Key Points
  • Record quarterly sales of $211k, the largest to date.
  • Annual sales increased 88% from FY25.
  • Secured $5M funding facility with Riverfort.
  • Successful market expansion in the Asia-Pacific, specifically Malaysia, Hong Kong, and Indonesia.
  • Progressed NervAlign® Nerve Guide Matrix program to Stage 3.
  • Continued investment in product development and commercial expansion.
  • Appointment of J4 as a second manufacturing partner for Empliq product range.
  • Operational cash outflows expected to remain consistent while pursuing revenue growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.